SAREPTA THERAPEUTICS, INC. Restructuring Charges
SAREPTA THERAPEUTICS, INC. (SRPT) reported Restructuring Charges of $42.01 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-03-02
- SAREPTA THERAPEUTICS, INC. restructuring charges for the quarter ending 2025-12-31 was $1.50M.
- SAREPTA THERAPEUTICS, INC. restructuring charges for the quarter ending 2025-09-30 was $40.51M.
- SAREPTA THERAPEUTICS, INC. restructuring charges for the quarter ending 2024-12-31 was $0.00.
- SAREPTA THERAPEUTICS, INC. restructuring charges for the quarter ending 2024-09-30 was $0.00.
- SAREPTA THERAPEUTICS, INC. restructuring charges for fiscal 2025 was $42.01M.
- SAREPTA THERAPEUTICS, INC. restructuring charges for fiscal 2024 was $0.00.
- SAREPTA THERAPEUTICS, INC. restructuring charges for fiscal 2023 was $0.00.
- SAREPTA THERAPEUTICS, INC. restructuring charges for fiscal 2017 was $3.02M, a 17.28% decline from fiscal 2016.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $42.01M derived: sum of 2 quarters · filed 2026-03-02 | $42.01M 10-K · filed 2026-03-02 | |
| 2025-09-30 | $40.51M 10-Q · filed 2025-11-06 | $40.51M 10-Q · filed 2025-11-06 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | ||
| 2023-12-31 | $0.00 10-K · filed 2026-03-02 | |||
| 2017-12-31 | $247.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $260.00K derived: sum of 2 quarters · filed 2019-02-28 | $2.78M derived: sum of 3 quarters · filed 2019-02-28 | $3.02M 10-K · filed 2019-02-28 |
| 2017-09-30 | $13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $2.54M derived: sum of 2 quarters · filed 2017-11-01 | $2.77M 10-Q · filed 2017-11-01 | $4.50M derived: sum of 4 quarters · filed 2018-03-01 |
| 2017-06-30 | $2.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $2.76M 10-Q · filed 2017-08-03 | $4.49M derived: sum of 3 quarters · filed 2018-03-01 | $5.48M derived: sum of 4 quarters · filed 2018-03-01 |
| 2017-03-31 | $236.00K 10-Q · filed 2017-05-04 | $1.97M derived: sum of 2 quarters · filed 2018-03-01 | $2.96M derived: sum of 3 quarters · filed 2018-03-01 | $3.51M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-12-31 | $1.73M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $2.72M derived: sum of 2 quarters · filed 2018-03-01 | $3.27M derived: sum of 3 quarters · filed 2018-03-01 | $3.65M 10-K · filed 2018-03-01 |
| 2016-09-30 | $990.00K 10-Q · filed 2016-11-07 | $1.54M derived: sum of 2 quarters · filed 2016-11-07 | $1.92M 10-Q · filed 2016-11-07 | |
| 2016-06-30 | $552.00K 10-Q · filed 2016-08-09 | $924.00K 10-Q · filed 2016-08-09 | ||
| 2016-03-31 | $388.00K 10-Q · filed 2016-05-05 | |||
| 2014-12-31 | $14.00K 10-K · filed 2015-02-26 | |||
| 2014-03-31 | $9.00K 10-Q · filed 2014-05-08 | $47.00K derived: sum of 2 quarters · filed 2015-02-26 | $102.00K derived: sum of 3 quarters · filed 2015-02-26 | $311.00K derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-12-31 | $38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | $93.00K derived: sum of 2 quarters · filed 2015-02-26 | $302.00K derived: sum of 3 quarters · filed 2015-02-26 | $764.00K 10-K · filed 2015-02-26 |
| 2013-09-30 | $55.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $264.00K derived: sum of 2 quarters · filed 2013-11-12 | $726.00K 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $209.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | $671.00K 10-Q · filed 2013-08-08 | ||
| 2013-03-31 | $462.00K 10-Q · filed 2014-05-08 | |||
| 2012-12-31 | $185.00K 10-K · filed 2015-02-26 | |||
| 2011-12-31 | $1.15M 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |